Show simple item record

dc.contributor.advisorDavey, Andrew
dc.contributor.authorRyan, Philip
dc.date.accessioned2020-07-02T05:09:56Z
dc.date.available2020-07-02T05:09:56Z
dc.date.issued2020-06-17
dc.identifier.doi10.25904/1912/694
dc.identifier.urihttp://hdl.handle.net/10072/395102
dc.description.abstractNeurodegenerative diseases are characterised by the progressive loss of neuron function and structure. The most prevalent neurodegenerative diseases are hypothesized to be due to the misfolding and accumulation of specific proteins in the brain. Alzheimer's disease (AD) is suspected to result from the aggregation of amyloid-[beta] [...] or tau proteins, Parkinson's disease (PD) from the aggregation of [alpha]-synuclein [...], and so on for numerous other diseases including Huntington's disease, amyotrophic lateral sclerosis, and Creutzfeldt-Jakob disease. There are no curative therapies for any of these fatal diseases, only palliative care is available in some cases currently. Research is currently focussed on modulating the aggregation processes common amongst the diseases. Various projects are dedicated to targeting the protein monomers, or small oligomeric assemblies, present at the early stages toward therapy. Modern strategies to target these proteins involve the use of peptide-based agents, effective at selectively binding the proteins through engaging with multiple sites along the protein sequences; and multitarget directed ligands (MTDL), which engage with multiple pathological factors to produce an overall beneficial effect. Here we set out to investigate various novel chemical scaffolds that we envisaged may prove effective at inhibiting protein aggregation mechanisms in the hopes of identifying new strategies and promising leads. [...]
dc.languageEnglish
dc.language.isoen
dc.publisherGriffith University
dc.publisher.placeBrisbane
dc.subject.keywordsNeurodegenerative diseases
dc.subject.keywordsAlzheimer’s disease
dc.subject.keywordstau proteins
dc.subject.keywordsParkinson’s disease
dc.titleAn Investigation Into Novel Molecular Strategies Targeting Neurodegenerative Diseases
dc.typeGriffith thesis
gro.facultyGriffith Health
gro.rights.copyrightThe author owns the copyright in this thesis, unless stated otherwise.
gro.hasfulltextFull Text
dc.contributor.otheradvisorRudrawar, Santosh
dc.contributor.otheradvisorKiefel, Milton
dc.contributor.otheradvisorKassiou, Michael
gro.identifier.gurtID000000023187
gro.thesis.degreelevelThesis (PhD Doctorate)
gro.thesis.degreeprogramDoctor of Philosophy (PhD)
gro.departmentSchool of Pharmacy and Pharmac
gro.griffith.authorRyan, Philip


Files in this item

This item appears in the following Collection(s)

Show simple item record